



## Tricida to Present at the Needham Virtual Healthcare Conference

April 8, 2021

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 20<sup>th</sup> Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 12:45 pm PT / 3:45 pm ET. Tricida will provide a company overview, business update and progress on the company's key initiatives.

A live webcast of the presentation will be accessible on the Tricida website at [IR.Tricida.com](http://IR.Tricida.com). An archive of the webcast will be available for 90 days following the presentation.

### About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veveimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veveimer slows progression of CKD in patients with metabolic acidosis and CKD. There are no FDA-approved treatments for chronic metabolic acidosis, a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit [www.tricida.com](http://www.tricida.com).

Contact:

Jackie Cossmon, IRC  
Tricida, Inc.  
Senior Vice President of Investor Relations and Communications  
[IR@Tricida.com](mailto:IR@Tricida.com)



Source: Tricida, Inc.